ANI Pharmaceuticals | ANIP - Selling And Administration Expenses


ANI Pharmaceuticals reported $94.86M in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.84B 205M Sep/2026
ANI Pharmaceuticals USD 94.86M 3.2M Sep/2026
Aurora Cannabis CAD 40.89M 515K Jun/2026
Canopy Growth CAD 33.99M 2.83M Jun/2026
Eli Lilly USD 3.12B 305M Sep/2026
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Heron Therapeutics USD 23.74M 605K Dec/2025
Hikma Pharmaceutical USD 288M 149M Dec/2025
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Novartis USD 3.08B 58M Sep/2026
Omeros USD 11.32M 2.48M Sep/2024
Perrigo USD 271.7M 3.01B Sep/2026
Sun Pharmaceuticals INR 24.89B 637.6M Mar/2025
Teva Pharmaceutical Industries USD 1.01B 27M Sep/2026